摘要
目的探讨125I粒子植入治疗肺癌所致上腔静脉综合征的临床疗效和安全性。方法 23例肺癌所致上腔静脉综合征患者均接受CT引导下125I粒子植入治疗,术后辅以脱水、利尿及抗感染,观察患者治疗前后的近、远期疗效及不良反应。结果术后1个月复查胸部CT,并结合临床资料评价疗效:完全缓解(CR)6例(26.1%),部分缓解(PR)14例(60.9%),病变稳定(SD)2例(8.7%),病变进展(PD)1例(4.3%),有效率(RR)为87.0%。随访12个月,6个月总生存期(OS)率为78.3%(18/23),12个月OS率为56.5%(13/23)。且治疗后未见明显血液及肝肾毒性,未见治疗相关的放射性损伤。结论125I粒子植入治疗肺癌所致上腔静脉综合征近、远期疗效肯定,不仅能迅速缓解临床症状、不良反应可耐受,且能延长患者的生存期。
Objective To observe the clinical therapeutic effect and safety of ^125I radioactive seed implantation for lung cancer patients with superior vena cava syndrome. Methods A total of 23 lung cancer patients with superior vena cava syndrome were treated with ^125I radioactive seed guided by the CT, postoperative supplemented by dehydration, diuresis and anti-infection treatment, the clinical efficacy and adverse reaction were observed after the treatment. Results The curative effect of all patients was evaluated by chest CT scanning and clinical findings one month postoperatively. The CR,PR,SD and PD was 26% ,60.8% ,8.6% and 4% respectively. The effective rate RR was 86.9%. All patients were followed up for 12 months. The overall survival rate of 6 months and 12 months as well as the median survive duration was 78% ,56.5% and 14.6 months respectively. There was no obvious blood and liver and kidney toxicity after treatment, and no treatment-related radioactive damage. Conclusion The clinical therapeutic effect of ^125I radioactive seed implantation for lung cancer patients with superior vena cava syndrome is define and adverse reactions are en- durable, and can prolong the patient＇s survival time.
出处
《临床军医杂志》
CAS
2015年第8期830-833,共4页
Clinical Journal of Medical Officers
